English

NATTO: 2018 Half Year Earnings Release

Report this content

Please find attached the Nattopharma Group 2018 Half Year Earnings Release.


Financial highlights for the First Half of 2018 are;

  •  Product revenue rose by 54,2% to NOK 47,2 million
  •  Gross Margin for the period was 41,7 %,
  •  Positive adjusted EBITDA of NOK 2,5 million

A presentation will be held via webcast by CEO Kjetil Ramsøy and SVP Global Sales & Marketing Christopher Speed at 10 am CET, Wednesday 22nd August 2018, followed by a Q&A session directly thereafter.

Please follow the below link to join the webcast;

http://webtv.hegnar.no/presentation.php?webcastId=92032125 


For more information, please contact:

Kjetil Ramsøy

CEO, NattoPharma

E-mail: kjetil.ramsoy@nattopharma.com


This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

This information is information that NattoPharma ASA (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above at 8:00 am CET on August 22nd, 2018.

Tags:

clinical trial osteoporosis cardiovascular health Vitamin K2 NattoPharma MenaQ7 Natural Vitamin K2

Documents & Links